Rebecca Araujo

DocwireNews

<div id="meta" class="style-scope ytd-watch-flexy">
<div id="meta-contents" class="style-scope ytd-watch-flexy">
<div id="container" class="style-scope ytd-video-secondary-info-renderer">
<div id="content" class="style-scope ytd-expander">
<div id="description" class="style-scope ytd-video-secondary-info-renderer">DocWire News spoke with Noopur Raje, MD, Director of the Center for Multiple Myeloma and Professor of Medicine at Harvard Medical School, about why multiple myeloma is associated with bone disease and how to manage this complication in patients.</div>
</div>
</div>
</div>
<h2 id="merch-shelf" class="style-scope ytd-watch-flexy">Interview Transcript</h2><p><strong>DW: Why are patients with MM at risk for bone disease?</strong></p><p><strong>Dr. Raje:</strong> Bone disease is a very common problem associated with multiple myeloma. It is in fact one of the pathognomonic features of myeloma. You know, when you think about CRAB criteria, the B in the CRAB stands for bone disease, and really it is present, I would argue, in the majority of myeloma patients. And the question is, how hard do we look for bone disease in patients with myeloma?</p><p>The reason for patients to have bone-related problems in the context of multiple myeloma is &hellip; and this is data which has gone back now years, wherein we&rsquo;ve shown that bone metabolism is significantly impacted in the context of myeloma. You have two different cell types: osteoclasts, which are the bone destroying cells; and osteoblasts, which are the bone forming cells, which are at complete odds in the context of myeloma. And we also know that the myeloma tumor cells, or the myeloma cells, feed into this vicious cycle wherein they cause an increase in osteoclastogenesis&mdash;that is the bone destroying cells&mdash;and there&rsquo;s very little, if any osteoblastic activity, that is the bone healing part of it. And there&rsquo;s a whole bunch of proteins and cytokines which we&rsquo;ve identified as factors which could be contributing to this. And this is that interaction between the tumor cell and the bone microenvironment, which then results in osteolytic disease, which is very classic of multiple myeloma. And, you know, if you want to think about osteolytic disease simplistically, it is an extreme form of osteoporosis wherein you can actually get those bony lesions that I&rsquo;m talking about.</p><p>And the reason it&rsquo;s really important to try and identify this and treat this proactively is because this can result in pretty significant morbidity in the way of bone pain fractures, and some of the acute sort of emergencies that we know of in oncology, such as hypercalcemia and cord compression can be a consequence of bone disease.</p><p><strong>DW: How do you address bone disease in patients with MM?</strong></p><p><strong>Dr. Raje:</strong> We should start out by thinking about, how do you diagnose bone disease in patients with multiple myeloma? And the International Myeloma Working Group has now come up with imaging modalities. Up until recently, we were using x-rays to diagnose bony-related problems, so scale surveys was part of routine workup for multiple myeloma patients. That has changed with the new guidelines and our recommendation is really to use either a whole body low-dose CAT scan, or a PET CT scan, or an MRI as an initial diagnostic tool. And the reason for that is x-rays are able to pick up bone disease in patients where you have more than 50% of bone loss, so the bone loss is pretty extreme by the time it shows up on an x-ray. And therefore it&rsquo;s important to use more sensitive criteria to pick up on bone disease, and this is sort of incorporated into the new working diagnosis of symptomatic multiple myeloma. So you don&rsquo;t necessarily have to have symptoms, but if on imaging modalities you have evidence of bone disease, that&rsquo;s enough for us to warrant treatment for myeloma and the associated bone disease as well. So imaging is really important. We&rsquo;ve completely replaced scale surveys, at least at my center, and we&rsquo;re doing whole body low-dose CAT scans. It&rsquo;s an easy test. It takes about a minute and a half. It does not expose a patient to that much more radiation, and it has a sensitivity of nearly 90%, so you&rsquo;re able to pick up bone disease in a lot of patients.</p><p>The other thing I will say is, you know, diagnosing is important, but trying to prevent some of the complications that I&rsquo;ve talked about with bone disease already very important to diminish the morbidity. And we also know that if you have the morbidity associated with bone disease, it is associated with worsening outcomes in terms of mortality as well. So it&rsquo;s critical that we pick up on it and critical that we proactively treat it. So the best treatment for bone disease for myeloma is treat the underlying myeloma. Once you treat the underlying myeloma, patients are going to have lot less in terms of bony-related complications. And the other things we have now for years is the use of minor bisphosphonates. So we use either pamidronate or zoledronic acid for the treatment of bone disease. And we now have a new monoclonal antibody, which is a RANK ligand inhibitor called Denosumab, which is also used for the treatment of myeloma related bone.</p></div>


Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Managing Bone Disease in Patients with Multiple Myeloma, with Dr. Raje

Oncology

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe